Editorial Commentary
DESTINY-Breast06 continues to explore HR+, HER2-negative metastatic breast cancer beyond DESTINY-Breast04
Translational Breast Cancer Research
2025;
6:
11
(24 January 2025)
Editorial Commentary
Understanding the NATALEE trial—from a methodologist stand of point
Translational Breast Cancer Research
2025;
6:
10
(24 January 2025)
Review Article
Advances in antibody-drug conjugates in the treatment of advanced triple-negative breast cancer: a narrative review
Translational Breast Cancer Research
2025;
6:
9
(24 January 2025)
Review Article
Breast cancer shares many epidemiological, lifestyle, and local hormonal and metabolic underpinnings with endometrial and ovarian cancer: a narrative review
Translational Breast Cancer Research
2025;
6:
8
(24 January 2025)
Review Article
Neurological symptom management in breast cancer meningeal carcinomatosis
Translational Breast Cancer Research
2025;
6:
7
(24 January 2025)
Review Article
Modern approaches to lymphatic surgery: a narrative review
Translational Breast Cancer Research
2025;
6:
6
(24 January 2025)
Review Article
De-escalation of axillary treatment in early breast cancer—a narrative review of current trials
Translational Breast Cancer Research
2025;
6:
5
(24 January 2025)
Review Article
Targeting low-risk triple-negative breast cancer: a review on de-escalation strategies for a new era
Translational Breast Cancer Research
2025;
6:
4
(24 January 2025)
Review Article
Recent advances and updated highlights in breast cancer pathologic diagnosis: a narrative review
Translational Breast Cancer Research
2025;
6:
3
(24 January 2025)
Original Article
Underlying factors that affect ultrasound conspicuity of breast biopsy markers: an exploratory study
Translational Breast Cancer Research
2025;
6:
2
(24 January 2025)
Editorial
Unveiling breast cancer disparities: comparative insights from Asian and Western populations
Translational Breast Cancer Research
2025;
6:
1
(24 January 2025)
